The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients
Author | Dina, Abushanab |
Author | Eldebs, Mohammed |
Author | Basha, Ahmed |
Author | Naseralallah, Lina |
Author | Kazkaz, Hadia |
Author | Moursi, Ahmed |
Author | Albazoon, Fatima |
Author | Wafi, Omar |
Author | Badran, Saif |
Author | Doi, Suhail A.R. |
Author | Al-Maadeed, Somaya |
Author | Alam, Mohammed Fasihul |
Author | Al-Badriyeh, Daoud |
Available date | 2022-09-08T05:10:26Z |
Publication Date | 2022-03-25 |
Publication Name | Current Problems in Cardiology |
Identifier | http://dx.doi.org/10.1016/j.cpcardiol.2022.101177 |
Citation | Abushanab D, Eldebs M, Basha A, Naseralallah L, Kazkaz H, Moursi A, Albazoon F, Wafi O, Badran S, Doi SAR, Al-Maadeed S, Alam MF, Al-Badriyeh D. The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients. Curr Probl Cardiol. 2022 Mar 25:101177. doi: 10.1016/j.cpcardiol.2022.101177. |
ISSN | 01462806 |
Abstract | This study answers the question of whether the health care costs of managing COVID-19 in preexisting cardiovascular diseases (CVD) patients increased or decreased as a consequence of evidence-based efforts to optimize the initial COVID-19 management protocol in a CVD group of patients. A retrospective cohort study was conducted in preexisting CVD patients with COVID-19 in Hamad Medical Corporation, Qatar. From the health care perspective, only direct medical costs were considered, adjusted to their 2021 values. The impact of revising the protocol was a reduction in the overall costs in non-critically ill patients from QAR15,447 (USD 4243) to QAR4337 (USD 1191) per patient, with an economic benefit of QAR11,110 (USD 3051). In the critically ill patients, however, the cost increased from QAR202,094 (USD 55,505) to QAR292,856 (USD 80,433) per patient, with added cost of QAR90,762 (USD 24,928). Overall, regardless of critical care status, the optimization of the initial COVID-19 protocols in patients with preexisting CVD did not reduce overall health care costs, but increased it by QAR80,529 (USD 22,117) per patient. |
Language | en |
Publisher | Elsevier |
Subject | COVID-19 cardiovascular diseases (CVD) |
Type | Article |
Open Access user License | http://creativecommons.org/licenses/by/4.0/ |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Computer Science & Engineering [2284 items ]
-
COVID-19 Research [799 items ]
-
Medicine Research [1382 items ]
-
Pharmacy Research [1234 items ]
-
Public Health [401 items ]